Policy experts and providers said his charge in the face of the tobacco industry and work to speed drug approvals has improved public health – but one group attacked his tenure, citing FDA’s decision on a powerful opioid.
At the Food and Drug Administration, the physician and venture investor promoted policies focused on innovating approaches to population health, opioids, chronic disease, AI and precision medicine.